Tag: Kate Rawson

Kate Rawson

Regulatory/FDA

The Real FDA Leadership Story Is New CDER Director Dr. Patrizia Cavazzoni

The Real FDA Leadership Story Is New CDER Director Dr. Patrizia Cavazzoni

June 7, 2021 — Despite ongoing speculation about who will be the next Commissioner of the Food and Drug Administration (FDA), “the real leadership story is at CDER,” the Center for Drug Evaluation and Research, according to Kate Rawson, senior editor of Prevision Policy. As Rawson explained during a June 4 webinar on “What’s Ahead […]

Read more

Washington Focus

Register Now: CHC Webinars Tackle Data Privacy Issues and the Future of the FDA

Register Now: CHC Webinars Tackle Data Privacy Issues and the Future of the FDA

April 26, 2021 – What happens in Washington doesn’t stay in Washington, and upcoming webinars will examine two of the areas most critical to healthcare marketing and communications: the use of personal data and protecting privacy, and what’s ahead for the FDA under new leadership. Registration is now open here for the two webinar programs, […]

Read more

Regulatory/FDA

Despite Strain on Resources During Pandemic, CDER Approves 53 Novel Drugs in 2020

Despite Strain on Resources During Pandemic, CDER Approves 53 Novel Drugs in 2020

Jan. 11, 2021 – When considering all of the COVID-19 challenges the FDA faced in 2020, it is noteworthy that the Center for Drug Evaluation and Research (CDER) approved 53 novel drugs last year, the second highest number of novel drug approvals in the past 10 years. In a forward to CDER’s 2020 report on […]

Read more

Washington Focus

Biden Plans Include Key Healthcare Appointments, ACA and, Maybe, Drug Pricing

Biden Plans Include Key Healthcare Appointments, ACA and, Maybe, Drug Pricing

Dec. 7, 2020 – President-elect Joe Biden announced on Dec. 7 his plans for filling key public health positions, including nominations for California Attorney General Xavier Becerra to be the next secretary of Health and Human Services and Dr. Rochelle Walensky, currently an infectious disease specialist at Massachusetts General Hospital, to become director of the […]

Read more

Washington Focus

Rawson Previews Biden COVID-19 Approach and Vaccine Roll-out

Rawson Previews Biden COVID-19 Approach and Vaccine Roll-out

Nov. 30, 2020 – Job one for President-elect Joe Biden is the response to the COVID-19 pandemic, which will represent a “marked difference in energy and tone” than that offered by the current administration and likely will include a new FDA Commissioner as well as the roll-out of COVID-19 vaccines, according to Kate Rawson, senior […]

Read more

Regulatory/FDA

HHS OIG Releases Fraud Alert on Speakers Bureaus

HHS OIG Releases Fraud Alert on Speakers Bureaus

Nov. 20, 2020 – In a rare special fraud alert issued Nov. 16, the Department of Health and Human Services Office of Inspector General (OIG) expresses skepticism about the value of company-sponsored speaker bureau events, outlines its concerns about “inherent fraud and abuse risks” associated with these programs, and offers a non-exhaustive list of the […]

Read more

Washington Focus

Coalition Webinar: Rawson’s Take on Post-election Healthcare Policy

Coalition Webinar: Rawson’s Take on Post-election Healthcare Policy

With a bitterly-contested campaign headlined by pandemic and recession nearly in the rear-view mirror and just days to go before the Nov. 3 election, communications and marketing professionals need to understand what the healthcare environment will look like when the dust settles. To help industry sort through the results and what they may mean for […]

Read more

Washington Focus

Rawson: Drug Pricing Concerns Will Dominate in Run-up to 2020 Election

Rawson: Drug Pricing Concerns Will Dominate in Run-up to 2020 Election

May 23, 2019 – Concern over drug pricing remains a healthcare policy issue that enjoys bipartisan support and will remain on the table for the Trump administration and Congress as campaigns for the 2020 election ramp up, according to Kate Rawson, senior editor at Prevision Policy. Speaking at a session of the Coalition for Healthcare […]

Read more

Regulatory/FDA

Gottlieb Departure from FDA Surprises Industry

Gottlieb Departure from FDA Surprises Industry

March 6, 2019 — FDA Commissioner Scott Gottlieb, M.D., recently stated that he was not leaving the FDA, so news of his departure at the end of the month sent shock waves through FDA-regulated industry yesterday. Citing a need to spend more time with his family, Gottlieb tweeted that he is “immensely grateful for the […]

Read more

Washington Focus

Midterms Delivered Divided Government, New Players

Midterms Delivered Divided Government, New Players

Nov. 30, 2018 – The 2018 midterm elections resulted in a divided Congress, questions about possible agency changes, and uncertainty related to drug pricing policy and the Affordable Care Act, according to Kate Rawson, senior editor, Prevision Policy and The RPM Report, who spoke at the Coalition for Healthcare Communication’s “2018 Post-election Conference on Healthcare […]

Read more